"Cystadenocarcinoma, Serous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
Descriptor ID |
D018284
|
MeSH Number(s) |
C04.557.470.200.025.480.240 C04.557.470.590.480.240
|
Concept/Terms |
Cystadenocarcinoma, Serous- Cystadenocarcinoma, Serous
- Cystadenocarcinomas, Serous
- Serous Cystadenocarcinoma
- Serous Cystadenocarcinomas
|
Below are MeSH descriptors whose meaning is more general than "Cystadenocarcinoma, Serous".
Below are MeSH descriptors whose meaning is more specific than "Cystadenocarcinoma, Serous".
This graph shows the total number of publications written about "Cystadenocarcinoma, Serous" by people in this website by year, and whether "Cystadenocarcinoma, Serous" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2011 | 1 | 0 | 1 |
2012 | 1 | 0 | 1 |
2013 | 3 | 0 | 3 |
2015 | 1 | 0 | 1 |
2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cystadenocarcinoma, Serous" by people in Profiles.
-
EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM. Mol Cancer Res. 2020 02; 18(2):278-286.
-
The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study. Int J Gynecol Cancer. 2015 Sep; 25(7):1248-52.
-
SOX2 expression associates with stem cell state in human ovarian carcinoma. Cancer Res. 2013 Sep 01; 73(17):5544-55.
-
SOX2 expression and prognostic significance in ovarian carcinoma. Int J Gynecol Pathol. 2013 Jul; 32(4):358-67.
-
Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer. Int J Gynecol Cancer. 2013 Jun; 23(5):839-45.
-
Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Hum Pathol. 2013 Mar; 44(3):329-35.
-
Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy. Virchows Arch. 2011 Aug; 459(2):183-91.